In our experimental design, we employed a sequential 5-day administration of doxorubicin followed by 5 days of HER-2-targeted antibody treatment to model the clinical practice in HER-2-positive breast cancer patients, where anthracycline-based regimens are typically followed by HER-2 inhibition. Here, ERBB2 is linked to breast carcinoma.